Navigation Links
SPO Reports Results for First Quarter 2013

NEW YORK, May 13, 2013 /PRNewswire/ --

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today financial results for the fiscal quarter ended March 31, 2013.

Total revenue for Q1-2013 was $149,000 compared to no revenues for the same period in 2012. In addition the Company has a current backlog of approximately $347,000 of purchase orders which it plans to deliver in the coming quarters. The increase in revenue was attributed to the continued success of the Company's partnership with HoMedics LLC for distribution of its private-labeled pulse oximeter known as the HoMedics Deluxe Pulse Oximeter.

In addition, the Company announced that it has secured working capital requirements via an equity investment in the Company that will provide funds for its business activities during 2013. With increased quarterly sales and the planned introduction of new wellness products, the Company believes it can now move forward to further expand its strategy in the consumer wellness market.

Michael Braunold, Chief Executive Officer of SPO commented: "We continue to build strength through our increased quarterly revenues and now via an equity investment into the Company. In addition we see further growth of sales with our distribution partner HoMedics LLC including expanded placement of the HoMedics Deluxe Pulse Oximeter within the US and Internationally. We look forward to capitalizing on these revenue opportunities throughout the rest of fiscal 2013."

SPO continues to work on other product opportunities and specifically on its wellness watch. Initial responses from retail category buyers to this new product opportunity have been positive and the Company is now focused on working with its timepiece manufacturing and distribution partner to realize this retail opportunity during fiscal 2013 and beyond. The Company is also continuing its dialogue with interested parties to incorporate its proprietary technology into other consumer mass-market product opportunities. They include a unique baby-monitor for parental reassurance when babies are sleeping and a sports watch to continuously measure heart-rate during exercise without the need of a chest strap.

Further details as to SPO's financial information and results of operations for the fiscal quarter ended March 31, 2013 are in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2013.

About SPO

SPO is a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-enhancing information within four key markets: medical care; sports and wellness; homecare monitoring and security. Its patented technology uses information gathered from the reflectance of light on the human body, in a noninvasive manner, to monitor key vital signs. The company manufactures its products in addition to licensing its technologies to appropriate client corporations for commercialization and distribution. For more information, visit

Forward Looking Statements

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, expectations as to  the realization of additional revenues from the order backlog, if any, of our efforts to expand distribution of products to additional mass market retailers, the ability to create additional strategic partnerships to aid in the distribution of products, expectations regarding the successful expansion of our product base to include, among other products, the wellness watch, the baby monitor and the sports watch, profitability, market acceptance of our products and new product applications, timing of new product launches, success of the Company's rebranding program, product performance, size of prospective markets, revenue assessments, marketing strategies, success of our restructured operations and plans, our ability to generate fees or raise capital to support our business operations and plan, the sufficiency and availability of working capital, changes in economic conditions generally and in more specifically, the introduction of competing products, changes in our operating strategy or development plans patent protection for our products and technologies, changes in economic conditions generally and in more specifically, in the markets we operate, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2012. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact regarding this release:

SOURCE SPO Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 Next week, December ... of Things (DoT ) co-located events covering the latest ... Internet of Things, will draw more than 3,000 design ... Convention Center. The events, combined show floor will ... --> --> ...
(Date:11/30/2015)... Nautilus Medical Inc. today announced worldwide availability of MatrixRay, ... The release of MatrixRay to the entire medical healthcare ... America) in Chicago - the ... --> --> MatrixRay is the first ... worldwide via a peer-to-peer exchange network of physicians and ...
(Date:11/30/2015)... November 30, 2015 ... adds a 2015 publication ... - 2015 with comprehensive analysis of ... of deal types, such as Mergers ... . ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... With ... footage, and with full control over customization, the possibilities are truly endless, all with ... position randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Third Molar ... that it has officially launched a sleek, mobile-ready and user-centric redesigned website. , ... new website clearly outlines the benefits that its SEO services provide to dentists ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of ... its VIP Woman of the Year Circle. She is recognized with this prestigious distinction ... exclusively for professional women, boasting more than 850,000 members and over 200 operating Local ...
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... . The directory is specialized and only includes chiropractic clinics in the US. ... competent and trustworthy alternative health practitioner when back pain sets in. When people ...
Breaking Medicine News(10 mins):